Sodium channel protein type 10 subunit alpha (NaV1.8)–Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1) protein–protein interface (NaV1.8–MAGI1 PPI)

The NaV1.8–MAGI1 protein–protein interface is a regulatory complex formed by the interaction between the voltage-gated sodium channel NaV1.8 (encoded by SCN10A) and the scaffolding protein Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1) (Liu et al., 2011, J Biol Chem). NaV1.8 is primarily expressed in nociceptive neurons of the dorsal root ganglia, where it is essential for the upstroke of action potentials during pain signaling (Akopian et al., 1999, Nat Neurosci). MAGI1 binds to the C-terminal PDZ-binding motif of NaV1.8, a process that facilitates the channel's trafficking to the plasma membrane and stabilizes its surface expression (Liu et al., 2011, J Biol Chem). By modulating this interface, researchers can selectively reduce the density of NaV1.8 channels on the neuronal surface, thereby decreasing the hyperexcitability associated with chronic pain states (Khanna et al., 2019, Pharmacol Ther). This targeting strategy offers a high degree of specificity, potentially avoiding the side effects seen with non-selective sodium channel blockers that affect the central nervous system or cardiac tissue (Cummins et al., 2007, J Physiol). Experimental tools like the TAT-NaV1.8-C decoy peptide have demonstrated that disrupting this PPI can effectively alleviate inflammatory and neuropathic pain in animal models (Liu et al., 2011, J Biol Chem). Consequently, the NaV1.8–MAGI1 interface is an emerging therapeutic target for the development of precision analgesics aimed at peripheral pain pathways.

Other names

SCN10A–MAGI1 interactionNaV1.8–MAGI1 complexNaV1.8–MAGI1 interfaceSCN10A–MAGI1 PPI

Inhibition of the interaction between the C-terminal PDZ-binding motif of NaV1.8 and the PDZ domains of MAGI1, leading to reduced surface expression of the sodium channel and decreased neuronal excitability.